Harrow Inc

Explore how Harrow Inc.’s insider selling, Phase‑3 trials, and strategic partnerships shape short‑term stock moves and long‑term growth prospects.

Opaleye Management’s recent 5,000‑share sale of Harrow Inc. is a tactical, liquidity‑focused pullback amid market volatility, not a signal of declining confidence—watch insider moves, earnings and drug pipeline for next‑step insights.